Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | PIK3CA | P42336 | 6/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | MTOR | P42345 | 2/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | PIK3R1 | P27986 | 3/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15879042 | 0.92 | MEN1 (0.50) | USP2SMN1; SMN2PIK3CAMAPTHTT | |
| SCHEMBL14387482 | 0.92 | MEN1 (0.50) | USP2SMN1; SMN2PIK3CAMAPTHTT | |
| SCHEMBL1409174 | 0.89 | GPR119 (0.49) | USP2SMN1; SMN2PIK3CAMAPTMEN1 | |
| SCHEMBL20692845 | 0.85 | PIK3CA (0.48) | USP2SMN1; SMN2PIK3CAPIK3R1 | |
| SCHEMBL24851269 | 0.85 | USP2 (0.54) | USP2SMN1; SMN2PIK3CAMAPTMTOR | |
| SCHEMBL10297496 | 0.85 | GPR119 (0.55) | USP2SMN1; SMN2PIK3CAMAPTMEN1 | |
| SCHEMBL21029959 | 0.85 | MAPT (0.50) | USP2SMN1; SMN2PIK3CAMAPTL3MBTL1 | |
| SCHEMBL12455887 | 0.84 | GPR119 (0.45) | SMN1; SMN2PIK3CAMAPTMEN1KMT2A | |
| SCHEMBL29434915 | 0.83 | PIK3CA (0.53) | USP2SMN1; SMN2PIK3CAMAPTMTOR | |
| SCHEMBL18153347 | 0.83 | PIK3CA (0.53) | USP2SMN1; SMN2PIK3CAMAPTMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240217960-A1 | TRIAZINE DERIVATIVE AS COVALENT INHIBITORS OF PI3K | UNIVERSITÄT BASEL (CH) | 2024-07-04 | — | — | US | disclosed |
| US-20240217960-A1 | TRIAZINE DERIVATIVE AS COVALENT INHIBITORS OF PI3K | UNIVERSITÄT BASEL (CH) | 2024-07-04 | — | — | US | disclosed |
| US-20240217960-A1 | TRIAZINE DERIVATIVE AS COVALENT INHIBITORS OF PI3K | UNIVERSITÄT BASEL (CH) | 2024-07-04 | — | — | US | disclosed |
| US-20240208957-A1 | TRIAZINE DERIVATIVE AS REVERSIBLE AND IRREVERSIBLE COVALENT INHIBITORS OF PI3K | UNIVERSITÄT BASEL (CH) | 2024-06-27 | — | — | US | disclosed |
| CN-117777042-A | Triazine hydroxamic acid derivative and preparation method and application thereof | 长沙医学院 | 2024-03-29 | — | — | CN | disclosed |
| EP-4320115-A1 | TRIAZINE DERIVATIVE AS REVERSIBLE AND IRREVERSIBLE COVALENT INHIBITORS OF PI3K | Universität Basel (CH) | 2024-02-14 | — | — | EP | disclosed |
| EP-4320110-A1 | TRIAZINE DERIVATIVE AS COVALENT INHIBITORS OF PI3K | Universität Basel (CH) | 2024-02-14 | — | — | EP | disclosed |
| CN-117396470-A | Triazine derivatives as reversible and irreversible covalent inhibitors of PI3 ks | 巴塞尔大学 | 2024-01-12 | — | — | CN | disclosed |
| US-20230014057-A1 | TREATMENT OF SKIN DISORDERS | TORQUR AG (CH) | 2023-01-19 | — | — | US | disclosed |
| CN-113200969-B | PI3K alpha selective inhibitor and preparation method and application thereof | 中国药科大学 | 2022-11-25 | — | — | CN | disclosed |
| US-20190284178-A1 | TREATMENT OF NEUROLOGICAL DISORDERS | TORQUR AG (CH) | 2019-09-19 | — | — | US | disclosed |
| US-20190224207-A1 | MULTIFUNCTIONAL INHIBITORS OF MEK/PI3K AND mTOR/MEK/PI3K BIOLOGICAL PATHWAYS AND THERAPEUTIC METHODS USING THE SAME | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-07-25 | — | — | US | disclosed |
| US-20190031682-A1 | DIFLUOROMETHYL-AMINOPYRIDINES AND DIFLUOROMETHYL-AMINOPYRIMIDINES | TORQUR AG (CH) | 2019-01-31 | — | — | US | disclosed |
| WO-2014005182-A1 | PHOSPHOINOSITIDE 3-KINASE (PI3K) INHIBITORS | MONASH UNIVERSITY (AU) | 2014-01-09 | — | — | WO | disclosed |
| US-20110053907-A1 | SUBSTITUTED PYRIMIDINES AND TRIAZINES AND THEIR USE IN CANCER THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2011-03-03 | — | — | US | disclosed |
| US-20110053907-A1 | SUBSTITUTED PYRIMIDINES AND TRIAZINES AND THEIR USE IN CANCER THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2011-03-03 | — | — | US | disclosed |
| US-20110053907-A1 | SUBSTITUTED PYRIMIDINES AND TRIAZINES AND THEIR USE IN CANCER THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2011-03-03 | — | — | US | disclosed |
| EP-2276750-A2 | SUBSTITUTED PYRIMIDINES AND TRIAZINES AND THEIR USE IN CANCER THERAPY | Auckland Uniservices Limited (NZ) | 2011-01-26 | — | — | EP | disclosed |
| WO-2009120094-A2 | SUBSTITUTED PYRIMIDINES AND TRIAZINES AND THEIR USE IN CANCER THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2009-10-01 | — | — | WO | disclosed |
| WO-2009120094-A2 | SUBSTITUTED PYRIMIDINES AND TRIAZINES AND THEIR USE IN CANCER THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2009-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053907-A1 | SUBSTITUTED PYRIMIDINES AND TRIAZINES AND THEIR USE IN CANCER THERAPY | PIK3CA, PIK3R5, PIK3CD | USP2 2368/4885SMN1; SMN2 3197/4885PIK3CA 1/4885 |
| US-20230014057-A1 | TREATMENT OF SKIN DISORDERS | RXFP3, CCR3, CBR3 | USP2 3054/4885SMN1; SMN2 2497/4885PIK3CA 4158/4885 |
| US-20190031682-A1 | DIFLUOROMETHYL-AMINOPYRIDINES AND DIFLUOROMETHYL-AMINOPYRIMIDINES | PIK3CA, MTOR, PIKFYVE | USP2 4318/4885SMN1; SMN2 2739/4885PIK3CA 1/4885 |
| US-20190284178-A1 | TREATMENT OF NEUROLOGICAL DISORDERS | CHRM1, CHRM2, C1R | USP2 3789/4885SMN1; SMN2 147/4885PIK3CA 4513/4885 |
| US-20240217960-A1 | TRIAZINE DERIVATIVE AS COVALENT INHIBITORS OF PI3K | PIK3R5, PIK3R1, PIK3R2 | USP2 453/4885SMN1; SMN2 4728/4885PIK3CA 12/4885 |
| US-20240208957-A1 | TRIAZINE DERIVATIVE AS REVERSIBLE AND IRREVERSIBLE COVALENT INHIBITORS OF PI3K | PIK3R5, PIK3R3, PIK3R1 | USP2 375/4885SMN1; SMN2 4675/4885PIK3CA 8/4885 |
| US-20190224207-A1 | MULTIFUNCTIONAL INHIBITORS OF MEK/PI3K AND mTOR/MEK/PI3K BIOLOGICAL PATHWAYS AND THERAPEUTIC METHODS USING THE SAME | MTOR, PIK3CA, MAPKAP1 | USP2 2846/4885SMN1; SMN2 3068/4885PIK3CA 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.